Mc-MMAE is primarily used in the field of targeted cancer therapy, particularly in the development of antibody-drug conjugates (ADCs). It functions as a potent cytotoxic agent that is attached to monoclonal antibodies, which are designed to specifically target cancer cells. Once the ADC binds to the target cancer cell, Mc-MMAE is released inside the cell, leading to cell death by inhibiting microtubule polymerization, which disrupts cell division. This targeted approach minimizes damage to healthy cells, making it a valuable component in treating various cancers, including lymphoma and solid tumors. Its application is a key advancement in precision medicine, offering improved efficacy and reduced side effects compared to traditional chemotherapy.